Skip to content
2000
image of Wound Healing Complications after Neoadjuvant Radiotherapy Combined with Targeted Therapies in Soft Tissue Sarcoma Patients

Abstract

Introduction/Objective

Significant advancements have been achieved with the use of targeted molecular therapies for the treatment of Soft Tissue Sarcomas (STS). However, data remain scarce about the potential benefits and toxicity of this therapeutic option. In this narrative review, we aim to better clarify the potential wound healing complications in STS patients undergoing neoadjuvant (NA) radiotherapy (RT) combined with targeted therapies.

Methods

We used the PubMed database to retrieve journal articles, and the inclusion criteria were all studies that illustrated the potential RT toxicity, combined with targeted therapies, in the NA setting of STS patients.

Results

Our search resulted in seven studies that fulfilled the inclusion criteria. Delayed wound complication rates were observed similarly to RT alone, while one study reported intolerable toxicity without referring specifically to wound complications.

Conclusion

The combination of RT with targeted therapies in STS seems to be effective and well tolerated. Due to the lack of studies with a high level of evidence, further research is required to enhance the existing knowledge for its potential value in this field.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/rrct/10.2174/0115748871354960250315170817
2025-05-07
2025-09-14

  • From This Site

    /content/journals/rrct/10.2174/0115748871354960250315170817
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Mastrangelo G. Coindre J.M. Ducimetière F. Dei Tos A.P. Fadda E. Blay J.Y. Buja A. Fedeli U. Cegolon L. Frasson A. Ranchère-Vince D. Montesco C. Ray-Coquard I. Rossi C.R. Incidence of soft tissue sarcoma and beyond. Cancer 2012 118 21 5339 5348 10.1002/cncr.27555 22517534
    [Google Scholar]
  2. Tiong S.S. Dickie C. Haas R.L. O’Sullivan B. The role of radiotherapy in the management of localized soft tissue sarcomas. Cancer Biol. Med. 2016 13 3 373 383 10.20892/j.issn.2095‑3941.2016.0028 27807504
    [Google Scholar]
  3. Canter R.J. Martinez S.R. Tamurian R.M. Wilton M. Li C.S. Ryu J. Mak W. Monsky W.L. Borys D. Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann. Surg. Oncol. 2010 17 10 2578 2584 10.1245/s10434‑010‑1156‑3 20556523
    [Google Scholar]
  4. Weitz J. Antonescu C.R. Brennan M.F. Localized extremity soft tissue sarcoma: Improved knowledge with unchanged survival over time. J. Clin. Oncol. 2003 21 14 2719 2725 10.1200/JCO.2003.02.026 12860950
    [Google Scholar]
  5. (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD), US National Cancer Institute 2002 1 6
    [Google Scholar]
  6. Wang D. Harris J. Kraybill W.G. Eisenberg B. Kirsch D.G. Ettinger D.S. Kane J.M. III Barry P.N. Naghavi A. Freeman C.R. Chen Y.L. Hitchcock Y.J. Bedi M. Salerno K.E. Severin D. Godette K.D. Larrier N.A. Curran W.J. Jr Torres-Saavedra P.A. Lucas D.R. Pathologic complete response and clinical outcomes in patients with localized soft tissue sarcoma treated with neoadjuvant chemoradiotherapy or radiotherapy. JAMA Oncol. 2023 9 5 646 655 10.1001/jamaoncol.2023.0042 36995690
    [Google Scholar]
  7. Viallard C. Larrivée B. Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis 2017 20 4 409 426 10.1007/s10456‑017‑9562‑9 28660302
    [Google Scholar]
  8. Matsumoto S. Batra S. Saito K. Yasui H. Choudhuri R. Gadisetti C. Subramanian S. Devasahayam N. Munasinghe J.P. Mitchell J.B. Krishna M.C. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res. 2011 71 20 6350 6359 10.1158/0008‑5472.CAN‑11‑2025 21878530
    [Google Scholar]
  9. Goedegebuure R.S.A. de Klerk L.K. Bass A.J. Derks S. Thijssen V.L.J.L. Combining radiotherapy with anti-angiogenic therapy and immunotherapy; a therapeutic triad for cancer? Front. Immunol. 2019 9 3107 10.3389/fimmu.2018.03107 30692993
    [Google Scholar]
  10. Yang T. Xiao H. Liu X. Wang Z. Zhang Q. Wei N. Guo X. Vascular normalization: A new window opened for cancer therapies. Front. Oncol. 2021 11 719836 10.3389/fonc.2021.719836 34476218
    [Google Scholar]
  11. Magnussen A.L. Mills I.G. Vascular normalisation as the stepping stone into tumour microenvironment transformation. Br. J. Cancer 2021 125 3 324 336 10.1038/s41416‑021‑01330‑z 33828258
    [Google Scholar]
  12. Rocchi L. Caraffi S. Perris R. Mangieri D. The angiogenic asset of soft tissue sarcomas: A new tool to discover new therapeutic targets. Biosci. Rep. 2014 34 6 e00147 10.1042/BSR20140075 25236925
    [Google Scholar]
  13. Heymach J.V. Angiogenesis and antiangiogenic approaches to sarcomas. Curr. Opin. Oncol. 2001 13 4 261 269 10.1097/00001622‑200107000‑00009 11429484
    [Google Scholar]
  14. Lugano R. Ramachandran M. Dimberg A. Tumor angiogenesis: Causes, consequences, challenges and opportunities. Cell. Mol. Life Sci. 2020 77 9 1745 1770 10.1007/s00018‑019‑03351‑7 31690961
    [Google Scholar]
  15. Wadlow R.C. Ryan D.P. The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer 2010 116 15 3537 3548 10.1002/cncr.25155 20564106
    [Google Scholar]
  16. Spigel D.R. Bendell J.C. McCleod M. Shipley D.L. Arrowsmith E. Barnes E.K. Infante J.R. Burris H.A. III Greco F.A. Hainsworth J.D. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clin. Colorectal Cancer 2012 11 1 45 52 10.1016/j.clcc.2011.04.002 21840771
    [Google Scholar]
  17. Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005 307 5706 58 62 10.1126/science.1104819 15637262
    [Google Scholar]
  18. Meyer J.M. Perlewitz K.S. Hayden J.B. Doung Y.C. Hung A.Y. Vetto J.T. Pommier R.F. Mansoor A. Beckett B.R. Tudorica A. Mori M. Holtorf M.L. Afzal A. Woodward W.J. Rodler E.T. Jones R.L. Huang W. Ryan C.W. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin. Cancer Res. 2013 19 24 6902 6911 10.1158/1078‑0432.CCR‑13‑1594 24132922
    [Google Scholar]
  19. Canter R.J. Borys D. Olusanya A. Li C.S. Lee L.Y. Boutin R.D. Christensen S.D. Tamurian R.M. Monjazeb A.M. Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. Ann. Surg. Oncol. 2014 21 5 1616 1623 10.1245/s10434‑014‑3543‑7 24554062
    [Google Scholar]
  20. Dadras M. Koepp P. Wallner C. Wagner J.M. Sogorski A. Lehnhardt M. Harati K. Behr B. Wound complications are a predictor of worse oncologic outcome in extremity soft tissue sarcomas. Surg. Oncol. 2020 33 126 134 10.1016/j.suronc.2020.02.016 32561077
    [Google Scholar]
  21. Potkrajcic V. Kolbenschlag J. Sachsenmaier S. Daigeler A. Ladurner R. Golf A. Gani C. Zips D. Paulsen F. Eckert F. Postoperative complications and oncologic outcomes after multimodal therapy of localized high risk soft tissue sarcoma. Radiat. Oncol. 2022 17 1 210 10.1186/s13014‑022‑02166‑4 36544149
    [Google Scholar]
  22. Callaghan C.M. Hasibuzzaman M.M. Rodman S.N. Goetz J.E. Mapuskar K.A. Petronek M.S. Steinbach E.J. Miller B.J. Pulliam C.F. Coleman M.C. Monga V.V. Milhem M.M. Spitz D.R. Allen B.G. Neoadjuvant radiotherapy-related wound morbidity in soft tissue sarcoma: Perspectives for radioprotective agents. Cancers (Basel) 2020 12 8 2258 10.3390/cancers12082258 32806601
    [Google Scholar]
  23. O’Sullivan B. Davis A.M. Turcotte R. Bell R. Catton C. Chabot P. Wunder J. Kandel R. Goddard K. Sadura A. Pater J. Zee B. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet 2002 359 9325 2235 2241 10.1016/S0140‑6736(02)09292‑9 12103287
    [Google Scholar]
  24. Albertsmeier M. Rauch A. Roeder F. Hasenhütl S. Pratschke S. Kirschneck M. Gronchi A. Jebsen N.L. Cassier P.A. Sargos P. Belka C. Lindner L.H. Werner J. Angele M.K. External beam radiation therapy for resectable soft tissue sarcoma: A systematic review and meta-analysis. Ann. Surg. Oncol. 2018 25 3 754 767 10.1245/s10434‑017‑6081‑2 28895107
    [Google Scholar]
  25. Lewin J. Khamly K.K. Young R.J. Mitchell C. Hicks R.J. Toner G.C. Ngan S.Y.K. Chander S. Powell G.J. Herschtal A. Te Marvelde L. Desai J. Choong P F M. Stacker S.A. Achen M.G. Ferris N. Fox S. Slavin J. Thomas D.M. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. Br. J. Cancer 2014 111 12 2254 2261 10.1038/bjc.2014.537 25321190
    [Google Scholar]
  26. Haas R.L.M. Gelderblom H. Sleijfer S. van Boven H.H. Scholten A. Dewit L. Borst G. van der Hage J. Kerst J.M. Nout R.A. Hartgrink H.H. de Pree I. Verhoef C. Steeghs N. van Coevorden F. A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities. Acta Oncol. 2015 54 8 1195 1201 10.3109/0284186X.2015.1037404 25920360
    [Google Scholar]
  27. Jakob J. Simeonova A. Kasper B. Ronellenfitsch U. Rauch G. Wenz F. Hohenberger P. Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: Results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03). Radiat. Oncol. 2016 11 1 77 10.1186/s13014‑016‑0654‑2 27255678
    [Google Scholar]
  28. van Meekeren M. Bovee J.V.M.G. van Coevorden F. van Houdt W. Schrage Y. Koenen A.M. Miah A.B. Zaidi S. Hayes A.J. Thway K. Krol S. Fiocco M. Gelderblom H. Steeghs N. Haas R.L. A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma. Acta Oncol. 2021 60 12 1557 1564 10.1080/0284186X.2021.1971294 34554030
    [Google Scholar]
  29. Kayton M.L. Weiss A.R. Xue W. Binitie O. Hayes Dixon A. Randall R.L. Sorger J.I. Hawkins D.S. Spunt S.L. Wang D. Million L. Terezakis S. Choy E. Okuno S.H. Venkatramani R. Chen Y.L. Scharschmidt T.J. Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children’s Oncology Group and NRG Oncology. J. Surg. Oncol. 2023 127 5 871 881 10.1002/jso.27205 36779385
    [Google Scholar]
  30. Tseng J.F. Ballo M.T. Langstein H.N. Wayne J.D. Cormier J.N. Hunt K.K. Feig B.W. Yasko A.W. Lewis V.O. Lin P.P. Cannon C.P. Zagars G.K. Pollock R.E. Pisters P.W.T. The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. Ann. Surg. Oncol. 2006 13 9 1209 1215 10.1245/s10434‑006‑9028‑6 16952046
    [Google Scholar]
  31. Cannon C.P. Ballo M.T. Zagars G.K. Mirza A.N. Lin P.P. Lewis V.O. Yasko A.W. Benjamin R.S. Pisters P.W.T. Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer 2006 107 10 2455 2461 10.1002/cncr.22298 17036354
    [Google Scholar]
  32. Griffin A.M. Dickie C.I. Catton C.N. Chung P.W.M. Ferguson P.C. Wunder J.S. O’Sullivan B. The influence of time interval between preoperative radiation and surgical resection on the development of wound healing complications in extremity soft tissue sarcoma. Ann. Surg. Oncol. 2015 22 9 2824 2830 10.1245/s10434‑015‑4631‑z 26018726
    [Google Scholar]
  33. Hoefkens F. Dehandschutter C. Somville J. Meijnders P. Van Gestel D. Soft tissue sarcoma of the extremities: Pending questions on surgery and radiotherapy. Radiat. Oncol. 2016 11 1 136 10.1186/s13014‑016‑0668‑9 27733179
    [Google Scholar]
  34. von Mehren M. Randall R.L. Benjamin R.S. Boles S. Bui M.M. Ganjoo K.N. George S. Gonzalez R.J. Heslin M.J. Kane J.M. III Keedy V. Kim E. Koon H. Mayerson J. McCarter M. McGarry S.V. Meyer C. Morris Z.S. O’Donnell R.J. Pappo A.S. Paz I.B. Petersen I.A. Pfeifer J.D. Riedel R.F. Ruo B. Schuetze S. Tap W.D. Wayne J.D. Bergman M.A. Scavone J.L. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2018 16 5 536 563 10.6004/jnccn.2018.0025 29752328
    [Google Scholar]
  35. Wang D. Abrams R.A. Radiotherapy for soft tissue sarcoma: 50 years of change and improvement. Am. Soc. Clin. Oncol. Educ. Book 2014 34 34 244 251 10.14694/EdBook_AM.2014.34.244 24857082
    [Google Scholar]
  36. Folkert M.R. Singer S. Brennan M.F. Kuk D. Qin L.X. Kobayashi W.K. Crago A.M. Alektiar K.M. Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity. J. Clin. Oncol. 2014 32 29 3236 3241 10.1200/JCO.2013.53.9452 25185087
    [Google Scholar]
  37. Swanson E.L. Indelicato D.J. Louis D. Flampouri S. Li Z. Morris C.G. Paryani N. Slopsema R. Comparison of three-dimensional (3D) conformal proton radiotherapy (RT), 3D conformal photon RT, and intensity-modulated RT for retroperitoneal and intra-abdominal sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 2012 83 5 1549 1557 10.1016/j.ijrobp.2011.10.014 22270176
    [Google Scholar]
  38. Röper B. Heinrich C. Kehl V. Rechl H. Specht K. Wörtler K. Töpfer A. Molls M. Kampfer S. von Eisenharth-Rothe R. Combs S.E. Study of preoperative radiotherapy for sarcomas of the extremities with intensity-modulation, image-guidance and small safety-margins (PREMISS). BMC Cancer 2015 15 1 904 10.1186/s12885‑015‑1633‑y 26573139
    [Google Scholar]
  39. Wang D. Zhang Q. Eisenberg B.L. Kane J.M. Li X.A. Lucas D. Petersen I.A. DeLaney T.F. Freeman C.R. Finkelstein S.E. Hitchcock Y.J. Bedi M. Singh A.K. Dundas G. Kirsch D.G. Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: Results of radiation therapy oncology group RTOG-0630 trial. J. Clin. Oncol. 2015 33 20 2231 2238 10.1200/JCO.2014.58.5828 25667281
    [Google Scholar]
  40. O’Sullivan B. Griffin A.M. Dickie C.I. Sharpe M.B. Chung P.W.M. Catton C.N. Ferguson P.C. Wunder J.S. Deheshi B.M. White L.M. Kandel R.A. Jaffray D.A. Bell R.S. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer 2013 119 10 1878 1884 10.1002/cncr.27951 23423841
    [Google Scholar]
  41. Davis A. Osullivan B. Turcotte R. Bell R. Catton C. Chabot P. Wunder J. Hammond A. Benk V. Kandel R. Goddard K. Freeman C. Sadura A. Zee B. Day A. Tu D. Pater J. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother. Oncol. 2005 75 1 48 53 10.1016/j.radonc.2004.12.020 15948265
    [Google Scholar]
  42. Whitelaw G.L. Blasiak-Wal I. Cooke K. Usher C. MacDougall N.D. Plowman P.N. A dosimetric comparison between two intensity-modulated radiotherapy techniques: Tomotherapy vs dynamic linear accelerator. Br. J. Radiol. 2008 81 964 333 340 10.1259/bjr/67084583 18344277
    [Google Scholar]
  43. Plowman P.N. Cooke K. Walsh N. Indications for tomotherapy/intensity-modulated radiation therapy in paediatric radiotherapy: Extracranial disease. Br. J. Radiol. 2008 81 971 872 880 10.1259/bjr/14878999 18941047
    [Google Scholar]
  44. Bray F.N. Simmons B.J. Wolfson A.H. Nouri K. Acute and chronic cutaneous reactions to ionizing radiation therapy. Dermatol. Ther. (Heidelb.) 2016 6 2 185 206 10.1007/s13555‑016‑0120‑y 27250839
    [Google Scholar]
  45. Caley M.P. Martins V.L.C. O’Toole E.A. Metalloproteinases and wound healing. Adv. Wound Care (New Rochelle) 2015 4 4 225 234 10.1089/wound.2014.0581 25945285
    [Google Scholar]
  46. Jacobson L.K. Johnson M.B. Dedhia R.D. Niknam-Bienia S. Wong A.K. Impaired wound healing after radiation therapy: A systematic review of pathogenesis and treatment. JPRAS Open 2017 13 92 105 10.1016/j.jpra.2017.04.001
    [Google Scholar]
  47. Haroon Z.A. Raleigh J.A. Greenberg C.S. Dewhirst M.W. Early wound healing exhibits cytokine surge without evidence of hypoxia. Ann. Surg. 2000 231 1 137 147 10.1097/00000658‑200001000‑00020 10636114
    [Google Scholar]
  48. Delanian S. Martin M. Bravard A. Luccioni C. Lefaix J.L. Abnormal phenotype of cultured fibroblasts in human skin with chronic radiotherapy damage. Radiother. Oncol. 1998 47 3 255 261 10.1016/S0167‑8140(97)00195‑3 9681888
    [Google Scholar]
  49. Akita S. Treatment of radiation injury. Adv. Wound Care (New Rochelle) 2014 3 1 1 11 10.1089/wound.2012.0403 24761339
    [Google Scholar]
  50. Radiation-Induced Skin Injury: A Challenging Issue in the Outpatient Wound Clinic. 2024 Available from: https://www.hmpgloballearningnetwork.com/site/twc/articles/radiation-induced-skin-injury-challenging-issue-outpatient-wound-clinic (Accessed on: March 4, 2024).
  51. Kraybill W.G. Harris J. Spiro I.J. Ettinger D.S. DeLaney T.F. Blum R.H. Lucas D.R. Harmon D.C. Letson G.D. Eisenberg B. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J. Clin. Oncol. 2006 24 4 619 625 10.1200/JCO.2005.02.5577 16446334
    [Google Scholar]
  52. Kao Y.S. Preoperative ultra-hypofractionation radiotherapy in extremity/trunk wall soft tissue sarcoma — A meta-analysis of prospective studies. Cancer Radiother. 2023 27 2 96 102 10.1016/j.canrad.2022.07.014 36028419
    [Google Scholar]
  53. Roohani S. Ehret F. Kobus M. Flörcken A. Märdian S. Striefler J.K. Rau D. Öllinger R. Jarosch A. Budach V. Kaul D. Preoperative hypofractionated radiotherapy for soft tissue sarcomas: A systematic review. Radiat. Oncol. 2022 17 1 159 10.1186/s13014‑022‑02072‑9 36104789
    [Google Scholar]
  54. Leite E.T.T. Munhoz R.R. Camargo V.P. Lima L.G.C.A. Rebolledo D.C.S. Maistro C.E.B. Busnardo F.F. Ferreira F.O. Salvajoli J.V. Carvalho H.A. Neoadjuvant stereotactic ablative radiotherapy (SABR) for soft tissue sarcomas of the extremities. Radiother. Oncol. 2021 161 222 229 10.1016/j.radonc.2021.06.027 34171452
    [Google Scholar]
  55. Gobo Silva M.L. Lopes de Mello C.A. Aguiar Junior S. D’Almeida Costa F. Stevanato Filho P.R. Santoro Bezerra T. Nakagawa S.A. Nascimento A.G. Werneck da Cunha I. Spencer Sobreira Batista R.M. Nicolau Daher U.R. Da Cruz Formiga M.N. Germano J.N. Catin Kupper B.E. De Assis Pellizzon A.C. Lopes A. Neoadjuvant hypofractionated radiotherapy and chemotherapy for extremity soft tissue sarcomas: Safety, feasibility, and early oncologic outcomes of a phase 2 trial. Radiother. Oncol. 2021 159 161 167 10.1016/j.radonc.2021.03.033 33798613
    [Google Scholar]
  56. Koseła-Paterczyk H. Teterycz P. Spałek M. Borkowska A. Zawadzka A. Wągrodzki M. Szumera-Ciećkiewicz A. Morysiński T. Świtaj T. Ługowska I. Castaneda-Wysocka P. Zdzienicki M. Goryń T. Rutkowski P. Efficacy and safety of hypofractionated preoperative radiotherapy for primary locally advanced soft tissue sarcomas of limbs or trunk wall. Cancers (Basel) 2021 13 12 2981 10.3390/cancers13122981 34198676
    [Google Scholar]
  57. Kalbasi A. Kamrava M. Chu F.I. Telesca D. Van Dams R. Yang Y. Ruan D. Nelson S.D. Dry S.M. Hernandez J. Chmielowski B. Singh A.S. Bukata S.V. Bernthal N.M. Steinberg M.L. Weidhaas J.B. Eilber F.C. A phase II trial of 5-day neoadjuvant radiotherapy for patients with high-risk primary soft tissue sarcoma. Clin. Cancer Res. 2020 26 8 1829 1836 10.1158/1078‑0432.CCR‑19‑3524 32054730
    [Google Scholar]
  58. Kubicek G.J. LaCouture T. Kaden M. Kim T.W. Lerman N. Khrizman P. Patel A. Xu Q. Lackman R. Preoperative radiosurgery for soft tissue sarcoma. Am. J. Clin. Oncol. 2018 41 1 86 89 10.1097/COC.0000000000000236 26535989
    [Google Scholar]
  59. Wunder J.S. Nielsen T.O. Maki R.G. O’Sullivan B. Alman B.A. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol. 2007 8 6 513 524 10.1016/S1470‑2045(07)70169‑9 17540303
    [Google Scholar]
  60. Frustaci S. De Paoli A. Bidoli E. La Mura N. Berretta M. Buonadonna A. Boz G. Gherlinzoni F. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003 65 Suppl. 2 80 84 10.1159/000073366 14586155
    [Google Scholar]
  61. Petrioli R. Coratti A. Correale P. D’Aniello C. Grimaldi L. Tanzini G. Civitelli S. Marsili S. Messinese S. Marzocca G. Pirtoli L. Francini G. Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. Am. J. Clin. Oncol. 2002 25 5 468 473 10.1097/00000421‑200210000‑00009 12393986
    [Google Scholar]
  62. Awada A. Hendlisz A. Gil T. Bartholomeus S. Mano M. de Valeriola D. Strumberg D. Brendel E. Haase C.G. Schwartz B. Piccart M. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer 2005 92 10 1855 1861 10.1038/sj.bjc.6602584 15870716
    [Google Scholar]
  63. Strumberg D. Richly H. Hilger R.A. Schleucher N. Korfee S. Tewes M. Faghih M. Brendel E. Voliotis D. Haase C.G. Schwartz B. Awada A. Voigtmann R. Scheulen M.E. Seeber S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 2005 23 5 965 972 10.1200/JCO.2005.06.124 15613696
    [Google Scholar]
  64. Ratain M.J. Eisen T. Stadler W.M. Flaherty K.T. Kaye S.B. Rosner G.L. Gore M. Desai A.A. Patnaik A. Xiong H.Q. Rowinsky E. Abbruzzese J.L. Xia C. Simantov R. Schwartz B. O’Dwyer P.J. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006 24 16 2505 2512 10.1200/JCO.2005.03.6723 16636341
    [Google Scholar]
  65. Escudier B. Eisen T. Stadler W.M. Szczylik C. Oudard S. Siebels M. Negrier S. Chevreau C. Solska E. Desai A.A. Rolland F. Demkow T. Hutson T.E. Gore M. Freeman S. Schwartz B. Shan M. Simantov R. Bukowski R.M. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007 356 2 125 134 10.1056/NEJMoa060655 17215530
    [Google Scholar]
  66. van der Graaf W.T.A. Blay J.Y. Chawla S.P. Kim D.W. Bui-Nguyen B. Casali P.G. Schöffski P. Aglietta M. Staddon A.P. Beppu Y. Le Cesne A. Gelderblom H. Judson I.R. Araki N. Ouali M. Marreaud S. Hodge R. Dewji M.R. Coens C. Demetri G.D. Fletcher C.D. Dei Tos A.P. Hohenberger P. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012 379 9829 1879 1886 10.1016/S0140‑6736(12)60651‑5 22595799
    [Google Scholar]
  67. Bitterman D.S. Safety and efficacy of combination targeted therapy and radiotherapy. Am. J. Hematol. Oncol. 2016 12 1 23 3
    [Google Scholar]
/content/journals/rrct/10.2174/0115748871354960250315170817
Loading
Wound Healing Complications after Neoadjuvant Radiotherapy Combined with Targeted Therapies in Soft Tissue Sarcoma Patients
Bentham Science Publishers ; https://doi.org/10.2174/0115748871354960250315170817
/content/journals/rrct/10.2174/0115748871354960250315170817
/content/journals/rrct/10.2174/0115748871354960250315170817
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Soft tissue sarcomas ; wound complications ; neoadjuvant treatment ; vascular endothelial growth factor ; targeted therapy ; radiotherapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test